p12CDK2AP1 Regulation of Normal and Neoplastic Growth

p12CDK2AP1 正常和肿瘤生长的调节

基本信息

项目摘要

DESCRIPTION (provided by applicant): The proposed plan for this NCI Mentored Career Development for Underrepresented Minorities K01 award is a two-year Mentored Phase, followed by a three-year Independent Phase. The Mentored Phase will provide for advanced training for the minority principal investigator under the co-mentorship of Dr. David Wong at the Laboratory of Head and Neck Cancer Research/Dental Research Institute and Dr. Lily Wu at the Vector-based Gene Therapy Laboratory/Crump Institute for Molecular Imaging at UCLA. This phase will provide the candidate with the opportunity to focus her efforts on research and development towards an academic career as an independent scientist. The overall goal of this proposal is to examine the role of p12 CDK2AP11 in regulating normal and neoplastic growth using in vivo model systems. Our rationale is that p12CDK2AP1, a cell cycle regulator and CDK2-associating protein commonly downregulated in -70% of head and neck cancers, is importantly involved in regulating normal and neoplastic growth in vivo. Several studies have shown that reexpressing p12 CDK2AP1 in tumor cells results in growth inhibition and induction of apoptosis, however little is known regarding the role of this molecule in regulating normal cell growth. During the Mentored Phase, the candidate will engage in investigating the role of pi2 CDK2AP1in normal development, and generating novel p12 CDK2AP1-based gene therapies for head and neck cancer treatment. In addition to the research training, a didactic component has been incorporated in the career development plan to enhance the candidate's overall career development. Defined milestones also will be in place to assess the candidate's scientific progress, particularly during transition to the Independent Phase. During the Independent Phase, the candidate will engage in examining the role of p12 CDK2AP1 in neoplastic growth by temporally ablating p12 CDK2AP1 expression specifically in adult head and neck tissues and developing novel tumor-targeted gene therapy strategies for future translational applications. The examination of the cellular and molecular responses to p12 CDK2AP1 ablation and therapy will provide insights into the functions of this cell cycle regulator in normal and neoplastic growth in vivo. This K01 mechanism is critical in assuring the time and resources needed for the development of the candidate into an independent research scientist in the field of cancer biology.
描述(由申请人提供):NCI针对未被充分代表的少数族裔的指导式职业发展K01奖项的建议计划是两年指导阶段,然后是三年独立阶段。导师阶段将为少数族裔首席研究员提供高级培训,由加州大学洛杉矶分校头颈癌实验室/牙科研究所的David Wong博士和加州大学洛杉矶分校基于载体的基因治疗实验室/CRump分子成像研究所的莉莉·吴博士共同指导。这一阶段将为候选人提供机会,将她的努力集中在研究和开发上,以独立科学家的学术生涯为目标。这项建议的总体目标是利用体内模型系统研究p12 CDK2AP11在调节正常和肿瘤生长中的作用。我们的理论基础是p12CDK2AP1,一种细胞周期调节蛋白和CDK2相关蛋白,在70%的头颈癌中普遍下调,在体内参与调节正常和肿瘤的生长。一些研究表明,在肿瘤细胞中重新表达p12 CDK2AP1会导致生长抑制和诱导凋亡,但对该分子在调节正常细胞生长中的作用知之甚少。在指导阶段,候选人将致力于研究Pi2 CDK2AP1在正常发育中的作用,并产生基于p12 CDK2AP1的头颈部癌症治疗的新基因疗法。除了研究性培训外,职业发展计划中还纳入了教学内容,以加强应聘者的整体职业发展。还将制定明确的里程碑,以评估候选人的科学进步,特别是在过渡到独立阶段期间。在独立阶段,候选人将致力于研究p12 CDK2AP1在肿瘤生长中的作用,方法是暂时消除p12 CDK2AP1在成人头颈部组织中的表达,并为未来的翻译应用开发新的肿瘤靶向基因治疗策略。对p12 CDK2AP1消融和治疗的细胞和分子反应的检测将有助于深入了解这种细胞周期调节因子在体内正常和肿瘤生长中的作用。这种K01机制对于确保候选人发展成为癌症生物学领域的独立研究科学家所需的时间和资源至关重要。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Marxa L Figueiredo其他文献

Marxa L Figueiredo的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Marxa L Figueiredo', 18)}}的其他基金

Facilitating Endogenous Bone Repair in Arthritis with Targeted IL-27 Sonodelivery
通过靶向 IL-27 声波传递促进关节炎的内源性骨修复
  • 批准号:
    10352199
  • 财政年份:
    2018
  • 资助金额:
    $ 4.67万
  • 项目类别:
Facilitating Endogenous Bone Repair in Arthritis with Targeted IL-27 Sonodelivery
通过靶向 IL-27 声波传递促进关节炎的内源性骨修复
  • 批准号:
    10088413
  • 财政年份:
    2018
  • 资助金额:
    $ 4.67万
  • 项目类别:
Disrupting tumor/bone malignant interactions with multifunctional cytokine sonodelivery
通过多功能细胞因子超声传递破坏肿瘤/骨恶性相互作用
  • 批准号:
    9894745
  • 财政年份:
    2016
  • 资助金额:
    $ 4.67万
  • 项目类别:
Disrupting tumor/bone malignant interactions with multifunctional cytokine sonodelivery
通过多功能细胞因子超声传递破坏肿瘤/骨恶性相互作用
  • 批准号:
    9262887
  • 财政年份:
    2016
  • 资助金额:
    $ 4.67万
  • 项目类别:
Pro-peptide gene delivery for treating prostate cancer bone metastases
用于治疗前列腺癌骨转移的前肽基因递送
  • 批准号:
    8681404
  • 财政年份:
    2013
  • 资助金额:
    $ 4.67万
  • 项目类别:
Pro-peptide gene delivery for treating prostate cancer bone metastases
用于治疗前列腺癌骨转移的前肽基因递送
  • 批准号:
    8585630
  • 财政年份:
    2013
  • 资助金额:
    $ 4.67万
  • 项目类别:
Preventing prostate cancer progression by ASC delivery of PEDF and IFNb
通过 ASC 输送 PEDF 和 IFNb 预防前列腺癌进展
  • 批准号:
    8446315
  • 财政年份:
    2012
  • 资助金额:
    $ 4.67万
  • 项目类别:
Preventing prostate cancer progression by ASC delivery of PEDF and IFNb
通过 ASC 输送 PEDF 和 IFNb 预防前列腺癌进展
  • 批准号:
    8289223
  • 财政年份:
    2012
  • 资助金额:
    $ 4.67万
  • 项目类别:
Preventing prostate cancer progression by ASC delivery of PEDF and IFNb
通过 ASC 输送 PEDF 和 IFNb 预防前列腺癌进展
  • 批准号:
    8700570
  • 财政年份:
    2012
  • 资助金额:
    $ 4.67万
  • 项目类别:
MECHANISMS OF XMRV ONCOGENESIS IN PROSTATE CELLS
XMRV 在前列腺细胞中的致癌机制
  • 批准号:
    8359781
  • 财政年份:
    2011
  • 资助金额:
    $ 4.67万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 4.67万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 4.67万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 4.67万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 4.67万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 4.67万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 4.67万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 4.67万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 4.67万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 4.67万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 4.67万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了